ConductScience.org, home

Paper36969208

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.

Furman MJ and 7 others. Front Immunol, 2023. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Papers, record 36969208. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969208

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system.
PubMed
Journal
Front Immunol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
2.81
iCite
Revised in PubMed
2024-10-06
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Furman MJMoritz J
2Meuth SGSven G
3Albrecht PPhilipp
4Dietrich MMichael
5Blum HHeike
6Mares JJan
7Milo RRon
8Hartung HPHans-Peter

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Autoimmune DiseasesMajor topic
Multiple SclerosisMajor topic
Humans
Autoantibodies
Central Nervous System
B-Lymphocytes

References127

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128893994Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.Proc Natl Acad Sci U S A2017https://conductscience.org/library/papers/28893994PubMed
235882229Microglia in multiple sclerosis: Protectors turn destroyers.Neuron2022https://conductscience.org/library/papers/35882229PubMed
333406479Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.Neurol Neuroimmunol Neuroinflamm2021https://conductscience.org/library/papers/33406479PubMed
430612739Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10.Cell2019https://conductscience.org/library/papers/30612739PubMed
533282676Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair.Brain Plast2020https://conductscience.org/library/papers/33282676PubMed
623684423The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.Cytokine Growth Factor Rev2013https://conductscience.org/library/papers/23684423PubMed
735970870Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.Nat Rev Neurol2022https://conductscience.org/library/papers/35970870PubMed
829143550
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mult Scler2019https://conductscience.org/library/papers/29143550PubMed
926065586Antibody-independent functions of B cells: a focus on cytokines.Nat Rev Immunol2015https://conductscience.org/library/papers/26065586PubMed
1034253922Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges.Nat Neurosci2021https://conductscience.org/library/papers/34253922PubMed
1118383069Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.Ann Neurol2008https://conductscience.org/library/papers/18383069PubMed
1234595983
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Mult Scler2022https://conductscience.org/library/papers/34595983PubMed
1329593838B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Ther Adv Neurol Disord2018https://conductscience.org/library/papers/29593838PubMed
1429305608Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.JAMA Neurol2018https://conductscience.org/library/papers/29305608PubMed
1526250739Immunopathology of multiple sclerosis.Nat Rev Immunol2015https://conductscience.org/library/papers/26250739PubMed
1630988116Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.J Immunol2019https://conductscience.org/library/papers/30988116PubMed
1734745138Semi-Automated Live Tracking of Microglial Activation in CX3CR1GFP Mice During Experimental Autoimmune Encephalomyelitis by Confocal Scanning Laser Ophthalmoscopy.Front Immunol2021https://conductscience.org/library/papers/34745138PubMed
1831617269Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis.Eur J Neurol2020https://conductscience.org/library/papers/31617269PubMed
1933649164CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS.Neurol Neuroimmunol Neuroinflamm2021https://conductscience.org/library/papers/33649164PubMed
2036001711Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.N Engl J Med2022https://conductscience.org/library/papers/36001711PubMed

See all 127 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42921194B-Cell-Related Neuroinflammation Across Central Nervous System Diseases: A Bibliometric and Science-Mapping Analysis, 2006-2026.J Inflamm Res2026https://conductscience.org/library/papers/42921194PubMed
42682178Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib.Clin Transl Sci2026https://conductscience.org/library/papers/42682178PubMed
41789172Editorial: Reviews in: multiple sclerosis and neuroimmunology.Front Neurol2026https://conductscience.org/library/papers/41789172PubMed
41787239Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.Neurol Ther2026https://conductscience.org/library/papers/41787239PubMed
41270166Antigen-specific B cell response regulation by IL-10-producing tolerogenic dendritic cells.Sci Adv2025https://conductscience.org/library/papers/41270166PubMed
40901465B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges.Front Immunol2025https://conductscience.org/library/papers/40901465PubMed
40089493Thyroid function and multiple sclerosis: a two-sample mendelian randomization study and mediation analysis.Sci Rep2025https://conductscience.org/library/papers/40089493PubMed
39872531Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review.Front Immunol2024https://conductscience.org/library/papers/39872531PubMed
39840055Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report.Front Immunol2024https://conductscience.org/library/papers/39840055PubMed
39814995Analysis of changes in the chemokine CXC ligand 13 in serum and cerebrospinal fluid of patients with neuromyelitis optica.Sci Rep2025https://conductscience.org/library/papers/39814995PubMed
39641859TWEAK and TNFɑ Pro-inflammatory Soluble Cytokines and their Specific Autoantibodies Secretion in Multiple Sclerosis Patients.Inflammation2025https://conductscience.org/library/papers/39641859PubMed
39524382The indications and safety of rituximab for the treatment of pediatric autoimmune diseases: a single-center retrospective study.Transl Pediatr2024https://conductscience.org/library/papers/39524382PubMed
38717637A new perspective on therapies involving B-cell depletion in autoimmune diseases.Mol Biol Rep2024https://conductscience.org/library/papers/38717637PubMed
38435981Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks.Immunotargets Ther2024https://conductscience.org/library/papers/38435981PubMed
38270296Immunosuppressive therapy and COVID-19 infection in patients with NMOSD.Immun Inflamm Dis2024https://conductscience.org/library/papers/38270296PubMed
38138980Epstein-Barr Virus and Human Endogenous Retrovirus in Japanese Patients with Autoimmune Demyelinating Disorders.Int J Mol Sci2023https://conductscience.org/library/papers/38138980PubMed
38129902Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.J Neuroinflammation2023https://conductscience.org/library/papers/38129902PubMed
37638037S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration.Front Immunol2023https://conductscience.org/library/papers/37638037PubMed

Download CSV of cited by

Genes30

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AQP4361PubTator's text mininghttps://conductscience.org/library/genes/361NCBI Gene
BTK695PubTator's text mininghttps://conductscience.org/library/genes/695NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD79A973PubTator's text mininghttps://conductscience.org/library/genes/973NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
HEPACAM220296PubTator's text mininghttps://conductscience.org/library/genes/220296NCBI Gene
IFNB13456PubTator's text mininghttps://conductscience.org/library/genes/3456NCBI Gene
IL103586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
IL6R3570PubTator's text mininghttps://conductscience.org/library/genes/3570NCBI Gene
JAK33718PubTator's text mininghttps://conductscience.org/library/genes/3718NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
MAL4118PubTator's text mininghttps://conductscience.org/library/genes/4118NCBI Gene
MOG4340PubTator's text mininghttps://conductscience.org/library/genes/4340NCBI Gene
MS4A1931PubTator's text mininghttps://conductscience.org/library/genes/931NCBI Gene
NEFL4747PubTator's text mininghttps://conductscience.org/library/genes/4747NCBI Gene

See all 30 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36969208

GET https://conductscience.org/api/papers/v1/36969208/references?page=2